Cirrhosis surgery: Difference between revisions
No edit summary |
|||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
==Transplantation== | ==Surgery== | ||
===Transplantation=== | |||
{{main|Liver transplantation}} | {{main|Liver transplantation}} | ||
If complications cannot be controlled or when the liver ceases functioning, [[liver transplantation]] is necessary. Survival from liver transplantation has been improving over the 1990s, and the five-year survival rate is now around 80%, depending largely on the severity of disease and other medical problems in the recipient.<ref> [http://www.emedicinehealth.com/liver_transplant/page11_em.htmE-medicine liver transplant outlook and survival rates]</ref> In the United States, the [[Model for End-Stage Liver Disease|MELD score]] <ref name="pmid2682175">{{cite journal |author=Cosby RL, Yee B, Schrier RW |title=New classification with prognostic value in cirrhotic patients |journal=Mineral and electrolyte metabolism |volume=15 |issue=5 |pages=261-6 |year=1989 |pmid=2682175 |doi=}}</ref> is used to prioritize patients for transplantation. Transplantation necessitates the use of immune suppressants ([[ciclosporin]] or [[tacrolimus]]). | If complications cannot be controlled or when the liver ceases functioning, [[liver transplantation]] is necessary. Survival from liver transplantation has been improving over the 1990s, and the five-year survival rate is now around 80%, depending largely on the severity of disease and other medical problems in the recipient.<ref> [http://www.emedicinehealth.com/liver_transplant/page11_em.htmE-medicine liver transplant outlook and survival rates]</ref> In the United States, the [[Model for End-Stage Liver Disease|MELD score]] <ref name="pmid2682175">{{cite journal |author=Cosby RL, Yee B, Schrier RW |title=New classification with prognostic value in cirrhotic patients |journal=Mineral and electrolyte metabolism |volume=15 |issue=5 |pages=261-6 |year=1989 |pmid=2682175 |doi=}}</ref> is used to prioritize patients for transplantation. Transplantation necessitates the use of immune suppressants ([[ciclosporin]] or [[tacrolimus]]). | ||
====Prevalence==== | |||
A recent study was completed between 1995 and 2006 that sought out to determine if there was a correlation between [[ursodeoxycholic acid]] (UDCA) and a decreases in liver transplantations for treating primary biliary cirrhosis.<ref name="pmid17900996">{{cite journal |author=Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N |title=Transplantation trends in primary biliary cirrhosis |journal=[[Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association]] |volume=5 |issue=11 |pages=1313–5 |year=2007 |month=November |pmid=17900996 |doi=10.1016/j.cgh.2007.07.015 |url=http://linkinghub.elsevier.com/retrieve/pii/S1542-3565(07)00718-5 |accessdate=2012-09-06}}</ref> In 2006 the results showed that over a ten year period the amount of liver transplantations needed for people with cirrhosis decreased by an average of 5.4 cases per year.<ref name="pmid17900996">{{cite journal |author=Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N |title=Transplantation trends in primary biliary cirrhosis |journal=[[Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association]] |volume=5 |issue=11 |pages=1313–5 |year=2007 |month=November |pmid=17900996 |doi=10.1016/j.cgh.2007.07.015 |url=http://linkinghub.elsevier.com/retrieve/pii/S1542-3565(07)00718-5 |accessdate=2012-09-06}}</ref> Although no causal relationship has been confirmed, this study has shown strong support to the notion that UDCA use has decreased the need for [[liver transplantation]] in patients presenting with primary biliary cirrhosis.<ref name="pmid17900996">{{cite journal |author=Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N |title=Transplantation trends in primary biliary cirrhosis |journal=[[Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association]] |volume=5 |issue=11 |pages=1313–5 |year=2007 |month=November |pmid=17900996 |doi=10.1016/j.cgh.2007.07.015 |url=http://linkinghub.elsevier.com/retrieve/pii/S1542-3565(07)00718-5 |accessdate=2012-09-06}}</ref> | |||
==References== | ==References== |
Revision as of 14:19, 6 September 2012
Cirrhosis Microchapters |
Diagnosis |
---|
Treatment |
Case studies |
Cirrhosis surgery On the Web |
American Roentgen Ray Society Images of Cirrhosis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
Surgery
Transplantation
If complications cannot be controlled or when the liver ceases functioning, liver transplantation is necessary. Survival from liver transplantation has been improving over the 1990s, and the five-year survival rate is now around 80%, depending largely on the severity of disease and other medical problems in the recipient.[1] In the United States, the MELD score [2] is used to prioritize patients for transplantation. Transplantation necessitates the use of immune suppressants (ciclosporin or tacrolimus).
Prevalence
A recent study was completed between 1995 and 2006 that sought out to determine if there was a correlation between ursodeoxycholic acid (UDCA) and a decreases in liver transplantations for treating primary biliary cirrhosis.[3] In 2006 the results showed that over a ten year period the amount of liver transplantations needed for people with cirrhosis decreased by an average of 5.4 cases per year.[3] Although no causal relationship has been confirmed, this study has shown strong support to the notion that UDCA use has decreased the need for liver transplantation in patients presenting with primary biliary cirrhosis.[3]
References
- ↑ liver transplant outlook and survival rates
- ↑ Cosby RL, Yee B, Schrier RW (1989). "New classification with prognostic value in cirrhotic patients". Mineral and electrolyte metabolism. 15 (5): 261–6. PMID 2682175.
- ↑ 3.0 3.1 3.2 Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N (2007). "Transplantation trends in primary biliary cirrhosis". Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 5 (11): 1313–5. doi:10.1016/j.cgh.2007.07.015. PMID 17900996. Retrieved 2012-09-06. Unknown parameter
|month=
ignored (help)